Abstract:Breast cancer (BC) is a common cause of morbidity and mortality, particularly in women. Moreover, the discovery of diagnostic biomarkers for early BC remains a challenging task. Previously, we [Jasbi et al. J. Chromatogr. B. 2019, 1105, 26-37] demonstrated a targeted metabolic profiling approach capable of identifying metabolite marker candidates that could enable highly sensitive and specific detection of BC. However, the coverage of this targeted method was limited and exhibited suboptimal classification of early BC (EBC). To expand the metabolome coverage and articulate a better panel of metabolites or mass spectral features for classification of EBC, we evaluated untargeted liquid chromatography quadrupole time-of-flight mass spectrometry (LC-QTOF-MS) data, both individually as well as in conjunction with previously published targeted LC-triple quadruple (QQQ)-MS data. Variable importance in projection scores were used to refine the biomarker panel, whereas orthogonal partial least squares-discriminant analysis was used to operationalize the enhanced biomarker panel for early diagnosis. In this approach, 33 altered metabolites/features were detected by LC-QTOF-MS from 124 BC patients and 86 healthy controls. For EBC diagnosis, significance testing and analysis of the area under receiver operating characteristic (AUROC) curve identified six metabolites/features [ethyl (R)-3-hydroxyhexanoate; caprylic acid; hypoxanthine; and m/z 358.0018, 354.0053, and 356.0037] with p < 0.05 and AUROC > 0.7. These metabolites informed the construction of EBC diagnostic models; evaluation of model performance for the prediction of EBC showed an AUROC = 0.938 (95% CI: 0.895-0.975), with sensitivity = 0.90 when specificity = 0.90. Using the combined untargeted and targeted data set, eight metabolic pathways of potential biological relevance were indicated to be significantly altered as a result of EBC. Metabolic pathway analysis showed fatty acid and aminoacyl-tRNA biosynthesis as well as inositol phosphate metabolism to be most impacted in response to the disease. The combination of untargeted and targeted metabolomics platforms has provided a highly predictive and accurate method for BC and EBC diagnosis from plasma samples. Furthermore, such a complementary approach yielded critical information regarding potential pathogenic mechanisms underlying EBC that, although critical to improved prognosis and enhanced survival, are understudied in the current literature. All mass spectrometry data and deidentified subject metadata analyzed in this study have been deposited to Mendeley Data and are publicly available (DOI: 10.17632/kcjg8ybk45.1).

Untargeted Saliva Metabonomics Study of Breast Cancer Based on Ultra Performance Liquid Chromatography Coupled to Mass Spectrometry with Hilic and Rplc Separations

[Application of Saliva Protein Fingerprints in the Diagnosis of Oral Squamous Cell Cancer by Surface Enhanced Laser Desorption Ionization Time of Flight Mass].

Largescale Multicenter Study of a Serum Metabolite Biomarker Panel for the Diagnosis of Breast Cancer

Integrative Analysis of Plasma Metabolomics and Proteomics Reveals the Metabolic Landscape of Breast Cancer

Investigation of Salivary Free Amino Acid Profile for Early Diagnosis of Breast Cancer with Ultra Performance Liquid Chromatography-Mass Spectrometry

The Early Diagnosis and Monitoring of Squamous Cell Carcinoma Via Saliva Metabolomics

Discovery And Preclinical Validation Of Salivary Transcriptomic And Proteomic Biomarkers For The Non-Invasive Detection Of Breast Cancer

Metabolomic Analysis of Plasma from Breast Cancer Patients Using Ultra-High-Performance Liquid Chromatography Coupled with Mass Spectrometry: An Untargeted Study

High-Throughput Salivary Metabolite Profiling on an Ultralow Noise Tip-Enhanced Laser Desorption Ionization Mass Spectrometry Platform for Noninvasive Diagnosis of Early Lung Cancer.

Development of a Headspace-Solid Phase Microextraction Gas Chromatography-High Resolution Mass Spectrometry Method for Analyzing Volatile Organic Compounds in Urine: Application in Breast Cancer Biomarker Discovery

Diagnostic Approach to Breast Cancer Patients Based on Target Metabolomics in Saliva by Liquid Chromatography with Tandem Mass Spectrometry

Early Breast Cancer Detection Using Untargeted and Targeted Metabolomics.

RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer.

Diagnosis of breast cancer using HPLC metabonomics fingerprints coupled with computational methods.

Use of ultra-high performance liquid chromatography-high-resolution mass spectroscopy to profile the metabolites from the serum of patients with breast cancer

[Analysis of Serum Metabonome of Patients with Breast Cancer by Gas Chromatography-Mass Spectrometry].

Measurement of Salivary Metabolite Biomarkers for Early Monitoring of Oral Cancer with Ultra Performance Liquid Chromatography-Mass Spectrometry.

Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles

Serum Metabonomics Study on Breast Cancer with UPLC/MS

Breast Cancer Detection Using Targeted Plasma Metabolomics

Salivary metabolite signatures of oral cancer and leukoplakia.